Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.

[1]  R. Poon,et al.  Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[2]  Ting-ting Zhang,et al.  Ultrasound-guided percutaneous microwave ablation treatment of initial recurrent hepatocellular carcinoma after hepatic resection: long-term outcomes. , 2015, Ultrasound in medicine & biology.

[3]  P. Böelle,et al.  Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. , 2015, Surgery.

[4]  S. Ye,et al.  Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients , 2015, Medical Oncology.

[5]  S. Ye,et al.  Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study , 2015, Medical Oncology.

[6]  M. Lee,et al.  Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients , 2015, Acta radiologica.

[7]  M. Colombo,et al.  Treatment of hepatocellular carcinoma: beyond international guidelines , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[8]  K. Sung,et al.  Transarterial Chemoembolization vs. Radiofrequency Ablation for the Treatment of Single Hepatocellular Carcinoma 2 cm or Smaller , 2014, The American Journal of Gastroenterology.

[9]  J. I. Lee,et al.  Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion , 2014, Journal of gastroenterology and hepatology.

[10]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[11]  Y. Kim,et al.  Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. , 2014, Radiology.

[12]  M. Kudo,et al.  Re‐evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[13]  D. J. Kim,et al.  Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. , 2014, World journal of gastroenterology.

[14]  S. Ye,et al.  Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria , 2014, BMC Gastroenterology.

[15]  T. Yamanaka,et al.  Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma , 2013, The British journal of surgery.

[16]  T. Seo,et al.  Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. , 2013, Journal of hepatology.

[17]  A. Shuster,et al.  Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular c , 2013, Journal of vascular and interventional radiology : JVIR.

[18]  S. Fan,et al.  Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma , 2011, World Journal of Surgery.

[19]  K. Sung,et al.  Medium-Sized (3.1–5.0 cm) Hepatocellular Carcinoma: Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Radiofrequency Ablation Alone , 2011, Annals of Surgical Oncology.

[20]  D. Gupta,et al.  Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature , 2010, Nutrition journal.

[21]  Hyun-Ki Yoon,et al.  Complete Necrosis After Transarterial Chemoembolization Could Predict Prolonged Survival in Patients with Recurrent Intrahepatic Hepatocellular Carcinoma After Curative Resection , 2010, Annals of Surgical Oncology.

[22]  J. Choi,et al.  Prognostic Factors and Optimal Treatment Strategy for Intrahepatic Nodular Recurrence After Curative Resection of Hepatocellular Carcinoma , 2008, Annals of Surgical Oncology.

[23]  Steven Gallinger,et al.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. , 2007, Surgery.

[24]  Donald L. Miller,et al.  Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2006, Journal of vascular and interventional radiology : JVIR.

[25]  Jung-Hwan Yoon,et al.  Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Fan,et al.  Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation , 2002, Annals of surgery.

[27]  Z. Tang,et al.  Hepatocellular carcinoma--cause, treatment and metastasis. , 2001, World journal of gastroenterology.

[28]  P. Tangkijvanich,et al.  Clinical Characteristics and Prognosis of Hepatocellular Carcinoma: Analysis Based on Serum Alpha-fetoprotein Levels , 2000, Journal of clinical gastroenterology.

[29]  S. Fan,et al.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. , 2000, Annals of surgery.

[30]  K Arai,et al.  Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. , 1993, Radiology.

[31]  J. Villeneuve,et al.  Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[32]  Jae Young Lee,et al.  Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: Long-Term Results and Prognostic Factors in 168 Patients with Cirrhosis , 2013, CardioVascular and Interventional Radiology.

[33]  R. Lencioni,et al.  Local-regional treatment of hepatocellular carcinoma. , 2012, Radiology.

[34]  C. Claussen,et al.  Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. , 2011, Academic radiology.

[35]  T. Fujiwara,et al.  A Prognostic Model and Treatment Strategy for Intrahepatic Recurrence of Hepatocellular Carcinoma after Curative Resection , 2010, World Journal of Surgery.